ContraFect (CFRX) Prices 10M Share Common Offering at $5/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
After-Hours Stock Movers 03/17: (UPST) (WSM) (FIVE) Higher; (TBIO) (CFRX) (SLDB) Lower (more...)
March 17, 2021 5:40 PM EDTAfter-Hours Stock Movers:
Upstart Holdings. (NASDAQ: UPST) 46% HIGHER; reported Q4 EPS of $0.07, $0.05 better than the analyst estimate of $0.02. Revenue for the quarter came in at $86.7 million versus the consensus estimate of $74.06 million. Upstream Worldwide, Inc. sees Q1 2021 revenue of $112-118 million, versus the consensus of $73.78 million. Upstream Worldwide, Inc. sees FY2021 revenue of $500 million, versus the consensus of $354.3 million.
Translate Bio (Nasdaq: TBIO) 14.5% LOWER; announced results from the second interim... More
ContraFect (CFRX) to Offer Common Stock
March 17, 2021 4:01 PM EDTContraFect Corporation (Nasdaq: CFRX) announced that it has commenced an underwritten public offering of shares of its common stock. ContraFect expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in... More
ContraFect Corp. (CFRX) PT Raised to $17.50 at Chardan Capital Markets
March 16, 2021 10:36 AM EDTChardan Capital Markets analyst Keay Nakae raised the price target on ContraFect Corp. (NASDAQ: CFRX) to $17.50 (from $15.00) while maintaining a Buy rating.
The analyst commented, "ContraFect has announced a new BARDA contract that will support the development of its lead compound, exebacase, a novel enzyme-based... More
